Quiroz-Mercado Hugo, Ustariz-González Orlando, Martinez-Castellanos Maria A, Covarrubias Paola, Dominguez Francisca, Sanchez-Huerta Valeria
Retina Service of Asociacion Para Evitar La Ceguera en México, Mexico City, Mexico.
Semin Ophthalmol. 2007 Apr-Jun;22(2):109-25. doi: 10.1080/08820530701420082.
This retrospective report describes our 20 months'experience using intravitreal injections of bevacizumab for the treatment of several retinal diseases. We describe our experience after 1765 intravitreal injections of bevacizumab in the treatment of different proliferative retinopathies - retinopathy of prematurity, choroidal neovascularization, diabetic retinopathy, among others. We believe that the findings reported in this study move us closer to a better treatment for different pathologies. However, further studies need to be performed in order to determine the safety and long-term efficacy of intravitreal bevacizumab either as first line therapy, after failure of conventional therapy, or in combination with conventional therapy.
本回顾性报告描述了我们使用玻璃体内注射贝伐单抗治疗多种视网膜疾病20个月的经验。我们介绍了在1765次玻璃体内注射贝伐单抗治疗不同增殖性视网膜病变（如早产儿视网膜病变、脉络膜新生血管、糖尿病性视网膜病变等）后的经验。我们认为本研究报告的结果使我们更接近针对不同病症的更好治疗方法。然而，需要进行进一步研究以确定玻璃体内注射贝伐单抗作为一线治疗、传统治疗失败后或与传统治疗联合使用时的安全性和长期疗效。
